Compare MOFG & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MOFG | OMER |
|---|---|---|
| Founded | 1934 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 861.6M | 628.9M |
| IPO Year | N/A | 2009 |
| Metric | MOFG | OMER |
|---|---|---|
| Price | $39.75 | $13.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $40.50 | $27.50 |
| AVG Volume (30 Days) | 189.4K | ★ 3.5M |
| Earning Date | 01-22-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.81 | N/A |
| Revenue | ★ $221,843,000.00 | N/A |
| Revenue This Year | $241.79 | N/A |
| Revenue Next Year | $7.28 | N/A |
| P/E Ratio | $13.92 | ★ N/A |
| Revenue Growth | ★ 504.86 | N/A |
| 52 Week Low | $24.62 | $2.95 |
| 52 Week High | $42.38 | $17.65 |
| Indicator | MOFG | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 53.10 | 58.02 |
| Support Level | $37.67 | $8.60 |
| Resistance Level | $39.23 | $17.63 |
| Average True Range (ATR) | 0.94 | 1.33 |
| MACD | -0.28 | 0.30 |
| Stochastic Oscillator | 47.81 | 60.02 |
MidWestOne Financial Group Inc is a bank holding company engaged in delivering relationship-based business and personal banking products and services. The Bank provides commercial loans, real estate loans, agricultural loans, credit card loans, and consumer loans. It also provides deposit products including demand and interest checking accounts, savings accounts, money market accounts, and time deposits. The Bank also provides products and services including treasury management, Zelle, online and mobile banking, debit cards, ATMs, and safe deposit boxes. The Bank offers its products and services through its network of full-service banking offices. the Bank's investments services department offers financial planning, investment advisory, and retail securities brokerage services.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.